OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)
Neovascular Age-related Macular Degeneration
About this trial
This is an interventional treatment trial for Neovascular Age-related Macular Degeneration
Eligibility Criteria
Inclusion Criteria:
- Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
- An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.
Main Exclusion Criteria:
- Any previous treatment for neovascular AMD.
- Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
- Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
Sites / Locations
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational siteRecruiting
- ShORe Investiagtional SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational siteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational Site
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investiagational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational Site
- ShORe Investigational Site
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational Site
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
- ShORe Investigational SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Sham Comparator
0.5 mg ranibizumab with Standard Dosing 2.0 mg OPT-302
0.5 mg ranibizumab with Extended Dosing 2.0 mg OPT-302
0.5 mg ranibizumab with sham
0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals. 2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals.
0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals. 2.0 mg OPT-302 intravitreal injection administered at 4-weekly intervals for three treatments, and then at 8-weekly intervals, with sham intravitreal injection administered at visits when OPT-302 is not.
0.5 mg ranibizumab intravitreal injection administered at 4-weekly intervals. Sham intravitreal injection administered at 4-weekly intervals.